Cogent Biosciences posts wider Q3 loss as costs rise

Cogent Biosciences

03/11/2025 14:08

Overview

Cogent Biosciences reports Q3 net loss of $80.9 mln, up from $70.6 mln in 2024

Cash position of $390.9 mln expected to fund operations through 2027

Upcoming PEAK and APEX trial results expected in Nov and Dec 2025

Outlook

Cogent plans to announce PEAK trial results in November 2025

Company expects APEX trial results in December 2025

Cogent aims to submit NDA for bezuclastinib by year-end 2025

Result Drivers

R&D EXPENSES - Increased R&D expenses due to ongoing clinical trials and preclinical programs

CASH POSITION - Strong cash position expected to fund operations through 2027

CLINICAL PROGRESS - Significant progress with upcoming trial results and regulatory submissions

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$80.93 mln
Q3 Income from Operations
-$83.35 mln
Q3 Operating Expenses
$83.35 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Cogent Biosciences Inc is $20.50, about 20.5% above its October 31 closing price of $16.30

Press Release: ID:nGNX9lpRgW

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)